- Home
- BCSF vs EWTX Comparison
BCSF vs EWTX Comparison
Compare BCSF & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- EWTX
- Stock Information
- Founded
- BCSF 2015
- EWTX 2017
- Country
- BCSF United States
- EWTX United States
- Employees
- BCSF N/A
- EWTX N/A
- Industry
- BCSF Finance/Investors Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- EWTX Health Care
- Exchange
- BCSF Nasdaq
- EWTX Nasdaq
- Market Cap
- BCSF 1.0B
- EWTX 1.2B
- IPO Year
- BCSF 2018
- EWTX 2021
- Fundamental
- Price
- BCSF $15.12
- EWTX $14.58
- Analyst Decision
- BCSF Hold
- EWTX Buy
- Analyst Count
- BCSF 4
- EWTX 8
- Target Price
- BCSF $16.50
- EWTX $40.13
- AVG Volume (30 Days)
- BCSF 292.4K
- EWTX 1.2M
- Earning Date
- BCSF 05-05-2025
- EWTX 05-08-2025
- Dividend Yield
- BCSF 0.79%
- EWTX N/A
- EPS Growth
- BCSF N/A
- EWTX N/A
- EPS
- BCSF 1.74
- EWTX N/A
- Revenue
- BCSF $284,993,000.00
- EWTX N/A
- Revenue This Year
- BCSF N/A
- EWTX N/A
- Revenue Next Year
- BCSF N/A
- EWTX N/A
- P/E Ratio
- BCSF $8.72
- EWTX N/A
- Revenue Growth
- BCSF N/A
- EWTX N/A
- 52 Week Low
- BCSF $13.20
- EWTX $10.60
- 52 Week High
- BCSF $19.21
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BCSF 46.65
- EWTX 41.67
- Support Level
- BCSF $14.69
- EWTX $13.82
- Resistance Level
- BCSF $15.58
- EWTX $17.30
- Average True Range (ATR)
- BCSF 0.38
- EWTX 1.02
- MACD
- BCSF 0.07
- EWTX 0.32
- Stochastic Oscillator
- BCSF 50.00
- EWTX 30.43
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.